In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Indaptus Therapeutics (INDP – Research Report), with a price target of $2.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jason McCarthy has given his Buy rating due to a combination of factors related to Indaptus Therapeutics’ promising clinical developments and strategic approach. The company has made significant progress with its Decoy20 platform, which is designed to stimulate the immune system against advanced solid tumors. The initiation of the P1b/2 trial combining Decoy20 with the anti-PD1 therapy, tislelizumab, marks a critical step forward, as early indications suggest that the combination is safe and well-tolerated.
Moreover, the trial’s design, which includes sequential patient enrollment and monitoring, ensures a thorough evaluation of safety and efficacy. The positive safety profile observed in previous studies, along with the potential to prime the immune system for anti-tumor activity, enhances the platform’s attractiveness. McCarthy’s valuation model, which considers multiple cancer indications and applies risk adjustments, supports a favorable price target, reinforcing the Buy rating.
INDP’s price has also changed dramatically for the past six months – from $1.000 to $0.340, which is a -66.00% drop .